{"id":37627,"date":"2020-08-17T06:01:20","date_gmt":"2020-08-17T06:01:20","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=37627"},"modified":"2020-08-17T06:01:20","modified_gmt":"2020-08-17T06:01:20","slug":"diversity-biotechnology-consortium","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/","title":{"rendered":"Diversity biotechnology consortium"},"content":{"rendered":"<p>A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium&#8217;s first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium&#8217;s purpose is to further the use of molecular diversity as a tool in drug design and in the study of mutating viruses.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium&#8217;s first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium&#8217;s purpose is to further the use of molecular diversity as a tool in drug design and in the study of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-37627","post","type-post","status-publish","format-standard","hentry","category-d"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Diversity biotechnology consortium - Definition of Diversity biotechnology consortium<\/title>\n<meta name=\"description\" content=\"A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium&#039;s first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium&#039;s purpose is to further the use of molecular diversity as a tool in drug design and in the study of mutating viruses.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diversity biotechnology consortium - Definition of Diversity biotechnology consortium\" \/>\n<meta property=\"og:description\" content=\"A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium&#039;s first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium&#039;s purpose is to further the use of molecular diversity as a tool in drug design and in the study of mutating viruses.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-17T06:01:20+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/\",\"name\":\"Diversity biotechnology consortium - Definition of Diversity biotechnology consortium\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2020-08-17T06:01:20+00:00\",\"dateModified\":\"2020-08-17T06:01:20+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium's first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium's purpose is to further the use of molecular diversity as a tool in drug design and in the study of mutating viruses.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diversity biotechnology consortium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Diversity biotechnology consortium - Definition of Diversity biotechnology consortium","description":"A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium's first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium's purpose is to further the use of molecular diversity as a tool in drug design and in the study of mutating viruses.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/","og_locale":"en_US","og_type":"article","og_title":"Diversity biotechnology consortium - Definition of Diversity biotechnology consortium","og_description":"A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium's first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium's purpose is to further the use of molecular diversity as a tool in drug design and in the study of mutating viruses.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/","og_site_name":"Glossary","article_published_time":"2020-08-17T06:01:20+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/","name":"Diversity biotechnology consortium - Definition of Diversity biotechnology consortium","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2020-08-17T06:01:20+00:00","dateModified":"2020-08-17T06:01:20+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium's first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium's purpose is to further the use of molecular diversity as a tool in drug design and in the study of mutating viruses.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/diversity-biotechnology-consortium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Diversity biotechnology consortium"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/37627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=37627"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/37627\/revisions"}],"predecessor-version":[{"id":37628,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/37627\/revisions\/37628"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=37627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=37627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=37627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}